Developments Cortexyme begins European screening for Phase 2/3 Alzheimer’s disease trial Cortexyme (NASDAQ:CRTX) began screening patients in Europe for its international Phase 2/3 trial, called GAIN, to evaluate COR388 in patients with mild-to-moderate Alzheimer’s disease (AD). The company has been... September 26, 2019